Informatie:
Fout:
ID
11708
Beschrijving
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo. https://clinicaltrials.gov/ct2/show/NCT00809965
Link
https://clinicaltrials.gov/ct2/show/NCT00809965
Trefwoorden
Versies (1)
- 28-07-15 28-07-15 -
Geüploaded op
28 juli 2015
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Rivaroxaban Acute Coronary Syndrome NCT00809965
Elegibility Criteria
- StudyEvent: ODM
Similar models
Elegibility Criteria
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Aspirin
Item
Currently receiving aspirin
boolean
C0004057 (UMLS CUI-1)
Acute coronary syndrome
Item
Hospitalized with symptoms suggestive of acute coronary syndrome
boolean
C0948089 (UMLS CUI-1)
Kidney failure
Item
Significant renal impairment
boolean
C0035078 (UMLS CUI-1)
Liver failure
Item
Significant liver disease
boolean
C0085605 (UMLS CUI-1)
Anticoagulant therapy
Item
Need for continued anticoagulant therapy
boolean
C0150457 (UMLS CUI-1)
Anticoagulant contraindicated
Item
Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy
boolean
C1531588 (UMLS CUI-1)